ArticleBMC cardiovascular disorders2025
A-kinase anchoring protein 1: an independent predictor of coronary artery disease.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCoronary artery disease (CAD) is the leading cause of death worldwide. A-kinase anchoring protein 1 (AKAP1), thought to regulate the function and structure of mitochondria, is enriched in the heart, where it plays a protective role. However, data on the serum AKAP1 concentration levels in patients with CAD are currently lacking. To address this, the serum levels of AKAP1 in patients with CAD were quantified and their predictive ability for CAD was evaluated in this study.
methodsA total of 255 patients referred for coronary angiography were included in this study and classified into two groups (CAD and non-CAD group). A comparative analysis of clinical data and serum AKAP1 concentration levels was performed between the two groups. The patients were then divided into quartiles according to AKAP1 levels. A multivariate logistic regression model was used to assess the independent association of AKAP1 with CAD.
resultsThe CAD group showed a lower AKAP1 concentration than the non-CAD group (P < 0.01). The AKAP1 level was correlated with a history of CAD (P < 0.001). The receiver operator characteristic (ROC) curve analysis showed a low ability of AKAP1 in predicting CAD (area under the ROC curve = 0.649). Finally, in the multivariate logistic regression model with the highest quartile as the reference, the lowest quartile of AKAP1 remained significantly associated with an increased risk for CAD (odds ratio (OR) = 5.677, 95% confidence interval [CI] 1.704 to 18.912, P = 0.005).
conclusionsOur results confirmed that serum AKAP1 levels are inversely associated with CAD and may therefore be used as a marker for CAD prediction. But additional studies are needed to confirm and further elucidate our results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.